Research data shows that neglected tropical diseases are becoming increasingly present in severely poverty-stricken areas throughout the United States.

Evidence shows that exotic illnesses not usually found in the United States are popping up in the poorest areas of the nation.

Known as neglected tropical diseases, these parasites and bacteria affect 1 billion people globally, according to the Centers for Disease Control and Prevention.

What Are Neglected Tropical Diseases?

The World Health Organization estimates that more than one-sixth of the world’s population suffers from at least one neglected tropical disease.
Image: PLOS

About 12 million U.S. residents have a neglected tropical disease, according to Dr. Peter Hotez, founding dean of the National School of Tropical Medicine at Baylor University’s College of Medicine. The study was conducted by Hotez and his team of researchers in 2014. It was later published in the journal PLOS.

Researchers discovered that tropical disease was most common in the poorest populations living in the world’s top 20 major economies.

“We already have dengue (and chikungunya) in Texas and in the Gulf Coast, and I think we’ll start to see transmission of both diseases in the coming years,” Hotez said.

The diseases are classified as neglected because they have been largely ignored by the medical community despite their creeping growth. Health professionals haven’t focused on finding ways to prevent or treat tropical diseases because they come with few or mild symptoms that do not usually lead to death.

The prevalence of a disease called chikungunya has been growing in the U.S. since it was first identified in 2013. Despite the fact that chikungunya has been an endemic in Africa and Asia for decades, there is currently is no vaccine or cure for the disease.

The amount of cases of chikungunya in the United States hit 2,700 last year, according to the CDC. Recently, 39 states had reported a total of 510 cases in 2015.

The spread of another disease, called Dengue fever, has been of increasing concern to scientists. About 300 million people in Southeast Asia and Latin America are currently affected by Dengue fever.

Dengue fever is transmitted through a mosquito called the Aedes aegypti. The Aedes aegypti, attracted to calm bodies of water and warm climates, has been seen in Florida and Texas.

This means there is a greater chance the disease-carrying mosquito will become native in these areas. The disease may also mutate and spread to other species of mosquitoes in the U.S.

Impact On Disadvantaged Children

Children living in low-income housing with poor sanitation have the highest risk of developing neglected tropical diseases.
Image: All Len All

The Southern United States houses about 45 million poor Americans who live in warm, humid climates where mosquitoes flourish.

The real problem behind these diseases is their long-term effects on children. The diseases could be debilitating for the physical and cognitive development in children raised in poverty, who are already at an economic disadvantage.

The majority of children who will contract these diseases are living in low-income housing conditions with poor sanitation. Because of the contaminated environment, these groups is more susceptible to neglected tropical diseases.

Effort To Reduce Neglected Tropical Disease

The United States has contributed funding to prevent and treat diseases abroad, but critics claim that the government needs to direct efforts to its own at-risk communities.
Image: Yahoo News

For the past nine years, the United States has contributed to the global effort to provide drugs that prevent or treat the seven most prevalent neglected tropical diseases, including hookworm, trachoma, river blindness and elephantiasis. The effort also attempts to improve sanitation and access to clean water in developing countries.

However, these programs have not been implemented in the United States. The lack of awareness about tropical diseases is particularly strong in impoverished areas, in addition to the fact that public health departments and hospitals are not equipped to take on crises related to tropical diseases.

Louisiana spends about $15 a year on public health for each resident. The state reported 10 cases of chikungunya and one case of dengue fever last year.

The Robert Wood Johnson Foundation conducted a study in 2014 and discovered that only half of states can efficiently detect, diagnose, prevent and respond to a disease threat.

According to Hotez, the Ebola outbreak in West Africa gave a new meaning to preparedness. The lack of readiness in dealing with the Ebola epidemic has prompted other nations to find new ways to face unexpected diseases.

Developing vaccines for tropical diseases, in addition to hospital preparedness, is extremely important. Many critics believe that Ebola could have been contained if these concerns had been addressed.

Later this month, the world’s top infectious disease experts will meet at the American Society of Tropical Medicine and Hygiene to discuss ways to improve the understanding of these diseases and how to prevent them.

According to Hotez, tropical diseases are neglected by the American medical community because they disproportionately affect the poorest individuals. He believes this will only change when the diseases spread to higher socioeconomic classes.

“It’s an inconvenient truth many people don’t want to recognize,” Hotez said.

The post Exotic Diseases Spread To Poorest Places In America appeared first on Citizens Report.

An Ebola vaccine was found to be 100 percent successful, but additional large-scale trials need to take place before its effectiveness is confirmed.

The epidemic in West Africa may finally come to an end after a new drug proved 100 percent successful in recent trials. Research that would have normally taken a decade was completed in just 12 months, which means the speed of the drug’s development is unprecedented.

The rVSV-ZEBOV vaccination came from a collaboration between various scientists, doctors, donors and drug companies. The World Health Organization took on the risk of sponsoring the trials, which marks another unusual element in this promising but out-of-the-ordinary drug advancement.

The Trials

Tests to prove the Ebola vaccine effective were completed in just 12 months in an extremely fast round of drug trials.
Via: Cidrap

The trials were conducted in Guinea and included 4,000 people. The outbreaks have recently shifted and become regional in nature, which created a perfect structure for testing the new vaccine. Researchers employed a “ring” trial design, where all individuals in each of the contaminated clusters were given the drug.

In the villages where ebola was present, researchers vaccinated the family, friends and neighbors who came into contact with the sick person, except for children, adolescents and pregnant women to ensure their safety. About 50 percent of villagers received the vaccination.

Some clusters were given the vaccination before being diagnosed with ebola. 2,014 people were vaccinated immediately and none developed the sickness. They were tested after 10 days had passed and their bodies had been able to develop an immunity. Other clusters were tested with a delayed vaccination method after infection was introduced. Out of 2,380 people, only 16 cases were reported.

“This trial dared to use a highly innovative and pragmatic design, which allowed the team in Guinea to assess this vaccine in the middle of an epidemic,” said Jeremy Farrar, director of the Wellcome Trust and one of the world’s leading experts on infectious disease. “It is a remarkable result which shows the power of equitable international partnerships and flexibility.”

The Supporters

The U.S., London, Norway, Canada, France, and Guinea collaborated to create the vaccine.
Via: Herzen

The drug is truly a result of widespread  international cooperation. The vaccine was originally developed by the Public Health Agency of Canada. Now, the vaccine is being tested and produced by Merck & Company, an American pharmaceutical company.

London’s biomedical research charity Wellcome Trust, the governments of Norway and Canada, Médecins sans Frontières from France, and the London School of Hygiene and Tropical Medicine came together to fund the vaccine. The majority of the staff who conducted the trials were from Guinea, which was 90 percent responsible for carrying out its first round of clinical research.

“This partnership also shows that such critical work is possible in the midst of a terrible epidemic. It should change how the world responds to such emerging infectious disease threats,” Farrar said.

The Trials Continue

The trials were conducted in Guinea by a primarily domestic medical staff.
Via: Humanosphere

The trials garnered promising results that rVSV-ZEBOV could be the vaccine that will stop future outbreaks before they start. However, trials will have to continue on a larger scale before anything is confirmed. From now on, all individuals who have come into contact with ebola-sickened persons will be offered the vaccine. It is also been approved for use in children and adolescents.

Other potential vaccines, one from GlaxoSmithKline and the other from Johnson & Johnson, may or may not be tested.

The trial for the Merck vaccine was a race against time, but other infected countries are encouraged to immediately replicate ring vaccinations to stop transmission and protect front-line workers.

“This new vaccine, if the results hold up, may be the silver bullet against Ebola, helping to bring the current outbreak to zero and to control future outbreaks of this kind,” said Børge Brende, the foreign minister of Norway.

The post Unusually Fast Ebola Vaccine Trials Prove Successful appeared first on Citizens Report.

The new vaccine is inhalable, so it will be able to be administered without the need of medical professionals.

New Aerosol Vaccine Protects Primates Against Ebola

A new type of vaccine has been created that could prove immensely helpful in preventing and fighting future Ebola outbreaks. A team at The University of Texas Medical Branch at Galveston along with the National Institutes of Health recently created an inhalable vaccine that has been shown to be effective in protecting primates from contracting the deadly virus.

The New Vaccine Can be Administered by Anybody

“A needle-free, inhalable vaccine against Ebola presents certain advantages,” said the head of the study, Michelle Meyer. “Immunization will not require trained medical personnel.”

The study looked at Ebola vaccinations given to non-human primates via either a liquid or aerosol. It discovered that aerosol vaccinations were just as effective at preventing Ebola as liquid vaccinations that had to be injected.

This marks the first occasion that an aerosol has successfully prevented a hemorrhagic fever. This promising study could provide a much greater solution to preventing and controlling the Ebola virus in the future.

The 2014 Ebola Outbreak Was the Worst in Recorded History

As of July 19, 2015, there were over 27,000 reported cases of Ebola with over 11,000 reported deaths. Many people at both the World Health Organization and Center for Disease Control believe these staggering numbers can be attributed to much of the weak medical infrastructure found throughout Africa.

When the disease first broke out, people throughout the continent were hesitant to label the disease as Ebola. The continent did not have proper procedures in place to handle the disease.

The three main countries that were hit by the Ebola outbreak were Sierra Leone, Guinea, and Liberia. As the disease began to spread, the three countries were not properly equipped to contain the devastating virus. Many scientists believe that the disease spread quicker than it should have.

Any Future Ebola Outbreaks Should be Much Less Deadly

Had a vaccination of this nature been present in the most recent outbreak, many deaths could have been prevented. Many villages and cities throughout Africa were forced to rely on city leaders and prominent voices rather than trained medical personnel. This allowed for the disease to spread in such a quick fashion. If this type of vaccine had been present, anyone living in these villages could have administered a vaccination rather than a doctor or nurse.

The team at the University of Texas at Galveston is hopeful that one day this type of vaccination method will be available for human use. They hope that it could be adapted to be used in situations where a solid and reliable medical infrastructure is not present or in some sort of biowarfare scenario.

This study has given the team hope that the study will be advanced further. It has yet to receive approval by an Investigative New Drug Application, but the team hopes that soon it will receive approval to develop a study testing the safety and efficacy for use in human adults.

The post New Vaccine Will Stop Ebola appeared first on Citizens Report.

Regulating homepathic remedies will illuminate those that are effective

Homeopathic medicine is made up of a combination of water that dissolves the active ingredient, and a few benign inactive ingredients. These unproven treatments are not usually regarded as dangerous, but as they continue to be marketed as cures for diseases, the FDA has finally decided to put its foot down. Hearings began in Washington in April to determine if manufacturers of homeopathic medicine would have to prove their products are a safe and effective treatment option.

Homeopathy includes a broad range of alternative cures, such as naturopathic medicines, ayurvedic medicines, eastern treatments like acupuncture, and much more. These treatments are sold as cures for issues as manageable as asthma, or even for diseases as serious as ebola. Despite its popularity, researchers worldwide extensively studied the effectiveness of homeopathic medicine and found that it does not work.

WordPress

The scientific community believes that a positive response to a homeopathic treatment is directly caused by the placebo effect, which is defined as the phenomenon that occurs when a patient is given an inactive substance but sees an improvement in their condition. In summary, the patient believed it would work, so it did.

Health investigators in the United Kingdom and Australia have concluded that homeopathy does not work, urging the United States to follow suit. In Canada, a law called the Ontario Homeopathy Act calls for a new kind of self-regulation. However, critics believe that this new law is not a solid form of regulation. On the other hand, some advocates of homeopathic medicine are in support of the new evaluations, believing that the altered restrictions will weed out the frauds.

It appears likely that the state of homeopathic medicine will change, but the question of how much remains. It’s possible that the new regulations will require more detailed labeling and added consumer warnings. But if the harder route is taken, homeopathic remedies will be held to the same standards, and undergo the same tests, as scientifically proven pharmaceuticals and treatments.

Big Pharma Controversy

There are skeptics saying to “follow the money.” They are saying that the push to regulate homeopathic remedies is backed by Big Pharma funding. The belief is that pharmaceutical companies do not want competition from alternative sources.

The post FDA Reevaluating Homeopathic Remedies appeared first on Citizens Report.

Primate testing has resulted in an effective vaccination for Ebola

Researchers, doctors and politicians across the globe have been working to put an end to the Ebola outbreak that ravaged West Africa and killed almost 10,000 people in 2014. As scientists attempted to discover the best preventative option, certain vaccine candidates came to the forefront.

The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. have since developed a vaccine that tackles Ebola Zaire, which is the West African Makona strain of the virus. There are five species of Ebola that have been identified, and the Zaire strain is credited with causing the 2014 outbreak.

The vaccine embeds the Ebola Zaire species within vesicular stomatitis, which is a form of the rabies virus that is not harmful to humans. The “Trojan horse” method allows the virus to enter into the body in a small dose so it can work toward creating a plan to fight it. The vaccine successfully caused a positive immune response when tested in a primate.

The vaccine is meant to be highly efficient and easily administered with a single dose. However, researchers are going a step further to solidify the safety of the vaccine. In addition to the original first-generation candidate, the team has developed two vaccines with weakened forms of the virus.

Contact between humans and nonhuman hosts with the Ebola Zaire virus, such as bats, will continue to rise. The development and distribution of an effective vaccine is a top priority. The candidates are currently under evaluation.

The post Single-Dose Ebola Vaccine is Effective appeared first on Citizens Report.

Alexis Benter

The military hospital in Freetown, Sierra Leone, conducted a controlled clinical trial in which 35 ebola patients received blood transfusions from donors who survived the disease. Though comparisons with the control arm of the study are not currently available, officials reported that 80 percent of the blood recipients lived. In a nation where the survival rate for the disease is below 50 percent, this is absolutely something to cheer about.

Could Antibody Proteins Block the Virus?

Proponents of the blood transfusion tactic believe that antibody proteins, which are slowly produced by the immune system, are most likely responsible for blocking the ebola virus in the weeks following infection. The treatment is particularly promising because blood plasma contains these antibodies. Since plasma can be donated more frequently than blood, this bodes well for patients in need. In addition, the tactic could potentially save more lives because the donated plasma can be stored for long periods of time.

Blood Treatments Prove Vital for Future Outbreaks

Though the initial findings are very promising, the blood plasma treatments will not have a significant impact in this current outbreak’s death toll, which has climbed past 9,253 individuals. However, these treatments will prove vital for future ebola outbreaks.

WordPress

Another benefit of the blood treatment is that it is essentially owned by the countries themselves. The medical industries won’t have to endure the headaches that come with paying high prices of buying pharmaceuticals from Big Pharma.

“The countries really liked the blood option more than the drugs because there is no manufacturer behind it and no international regulatory approvals required,” says David Wood, a virologist at the World Health Organization.

Despite the benefits, the blood transfusion tactic is not yet ready to be implemented on a massive scale. At the blood bank headquarters in Freetown, donor blood is stored in a rusted refrigerator, and lab technicians enter vital data on outdated computers. There is also the threat of blood spoiling from unreliable electricity.

Thankfully, the World Bank granted $200,000 to the Sierra Leonean blood trial, and several other donors committed more than $3.3 million to the plasma studies. A portion of this budget will go toward the purchase of medical equipment, refrigerators and infrastructure. Professionals are hopeful that the blood transfusion tactic will one day put an end to the ebola virus for good.

The post Blood Transfusions Potential Cure for Ebola appeared first on Citizens Report.

Alexis Benter

The Ebola epidemic in 2014 represents the largest outbreak of the deadly disease in the recorded history of mankind. The devastating illness has killed more than 10,000 people and affected more than 22,000.

While the virus sprinted through West African nations, many global organizations criticized the World Health Organization’s African leadership as being slow and weak to respond to the outbreak. Some cite the WHO’s response in Africa as a primary reason that the Ebola outbreak spread so quickly.

However, there is hope for the WHO’s African office. The organization appointed Dr. Matshidiso Moeti as the new regional director for Africa. Dr. Moeti brings a wide array of experience and knowledge to the organization, which was once seen as a resume booster for political officials with little experience but many connections.

Hope For A Better African System

Dr. Moeti acknowledged the WHO’s weak response to the initial Ebola outbreak and placed attention to Ebola as her number one priority. She plans on eliminating the spread of the disease and reducing the number of individuals affected to zero. While the tragedy surrounding Ebola is immense, Moeti hopes that it will serve as a catalyst to improve health care in Africa as a whole and make it a priority to improve the quality of health care in African nations.

Talk Radio News

As a native of the Republic of Botswana, Moeti brings a wealth of knowledge regarding health care and infectious diseases. She possesses more than 35 years of health care experience with WHO, UNICEF, UNAIDS and the Botswana Ministry of Health. She was at the head of the WHO Regional Office for Africa’s attempts at treating the HIV/AIDS pandemic and was the Director of Noncommunicable Diseases from 2008 to 2011. Moeti received degrees in medical and public health from the University of London and the London School of Hygiene and Tropical Medicine.

Dr. Moeti provides an optimistic attitude towards the situation unfolding in Africa right now. This attitude will be crucial to ending the Ebola crisis as well as improving Africa’s health care system.

“I commit myself and colleagues to build on what we have created so far and I am confident that we will ride on the positive things happening in the Region,” said Moeti in an article on the World Health Organization’s website.

Featured image courtesy of: Facebook

The post New WHO Regional Director For Africa Plans To Terminate Ebola appeared first on Citizens Report.

As headlines shift away from the Ebola outbreak that flourished in 2014, it’s easy to forget the disease that “sickened more than 200,000 people in West Africa, and killed at least 8,200, according to the World Health Organization (WHO).”

Although current data shows that the number of new cases is dropping in all three of the hardest-hit West African countries (Sierra Leone, Liberia and Guinea), and a recent study shows that Ebola could possibly be eliminated from the country of Liberia by June, scientists are working hard to create a vaccine for the disease.

“The idea of predicting infectious disease is relatively new. It’s not like weather predictions,” says Jeffrey Shaman, an associate professor at Mailman School of Public Health, in an interview with NPR. With this in mind, several companies are racing to test their experimental vaccines in an effort to put a standstill to the deadly disease.

Currently, there are three experimental vaccines that show signs of success. All three of them are being tested in humans in a remarkably fast pace due to the urgency of the situation.

The Top Three Most Promising Vaccinations

1. Johnson & Johnson’s Ebola Vaccine: The vaccine carries modified versions of a human cold virus and the smallpox virus, along with small parts of the genetic material of the Ebola virus. The little amount of Ebola contained may be enough to administer an immune response against the virus—meaning the body can find a way to resist the effects.

J & J started their Phase 1 trial to test the vaccine on healthy volunteers in the United Kingdom on Tuesday, Jan. 6. The purpose of the first round is to identify potential side effects of the drug before it’s administered to a larger group of people. The vaccine is being developed by J & J’s Janssen Pharmaceutical Cos. and Bavarian Nordic. Over 400,000 regimens of this vaccine have been produced that could then be used in larger trials by April.

2. GlaxoSmithKline’s Ebola Vaccine: This vaccine is further along in its development, having its Phase 1 results already published in The New England Journal of Medicine on Nov. 26, 2014. The research showed that the vaccine appeared to be effective in test subjects.

The study was done on 20 healthy adult volunteers within the United States who eventually produced antibodies against the Ebola virus. According to Reuters, Phase 2 of the trial on a larger group of people may begin in February in Africa.

3. Merck & Co.’s Ebola Vaccine: This vaccine experienced some complications in its Phase 1 trials when one of the volunteers began to experience joint pain. Testing was immediately stopped, and resumed later on when the symptoms resolved without treatment, according to the University of Geneva hospital in Switzerland.

A lower dosage of the vaccine is now being administered in trials. There has long been a debate on the urgency of a vaccine development for this deadly infectious virus in the past—which you can read all about here.

But, with monetary and medical complications pushed to the side, a safe and effective Ebola vaccination is well on its way to being used in the real world. The Ebola vaccine is expected to be available for mass use in summer 2015 at the earliest, according to the WHO.

The post Three Promising Ebola Vaccinations are in the Works appeared first on Citizens Report.

Turn on the news and chances are you will be hear about the Ebola virus.

The 2014 Ebola epidemic is noted as the largest in history, especially affecting West African countries Guinea, Liberia and Sierra Leone. And with 13,567 people known to have contracted the virus and over 5,000 dead, the question that comes up is: Why so many? Well this is where the debate begins.

Why Isn’t There Already a Vaccine for Ebola?

This is the question that many of us are asking right now. The World Health Organization blames the drug industry’s drive for profit. WHO Director Dr. Margaret Chan states “a profit-driven industry does not invest in products for markets that cannot pay,” referring to the impoverished African countries.

The Incredible Expense, That’s What.

One of the main reasons that there has been no Ebola vaccine out on the market yet is because of the large cost and time associated with it. It is estimated that its costs about $1.89 billion to introduce a new drug to the market. Pharmaceutical companies have a need to stay profitable. With the costs of developing new drugs being so high, Big Pharma is averse to investing in a drug that will not earn back its cost of development. This reality leads to the lack of drugs being developed for illnesses, such as Ebola, that affect poor African nations.

What’s Next?

The damage that the virus has done is pretty obvious. Maybe with the virus spreading to other countries–like the United States–the drug industry will take this as a push for developing a vaccine. The WHO says that experimental vaccine testing on humans could begin in early 2015. But for now, many can agree that a solution to this epidemic is needed–fast.

The post The Ebola Vaccine Debate: Ethics and Profit appeared first on Citizens Report.

Photo taken from Reddit.com

Just because its unlikely for one to get ebola doesn’t mean ignorance should be practiced. Knowledge is power as they say. Build a shield of knowledge to protect yourself from that lethal Ebola virus.

Credit: Infographic.ca

1. Bodily fluids from infected people could only give you Ebola if their

• spit
• blood
• boogers
• vomit
• sweat
• urine
• poop, or
• “other bodily fluid”

2. came into contact with your

• eyes
• nose
• mouth
• an open cut, or your
• hoo-hah (another good reason to practice safe sex).
  

  ---

Even if you were in the same room with someone with ebola, you wouldn’t really even have much reason to worry at all. Wikipedia says:

The possibility of transmission between non-seat-mate airline passengers is also generally ruled out.

Just to be clear, ebola cannot spread through:

Courtesy of Center for disease control (CDC).

Are you worried about someone giving you ebola? Just trust your eyes.
If someone looks pretty normal, then you probably should relax. People with ebola can only spread the disease when they are showing symptoms.

What does a really sick ebola-infested person look like? Find that out and learn even more below.

Credit: Infographic.ca

What should you do if you end up getting ebola? The same thing you should do even if you only think you have ebola…

Original photo from Center of Disease Control (CDC)

If you think you have ebola, call a damn doctor! Call the CDC @ 1-800-232-4636. Call 911. Call some medical professional and try not to infect anyone.

People should focus their energy on self-educating, not on worrying about what could go wrong with them. That’s true in general, not just with ebola. If someone did want to worry about something, though, they’d be better served worrying about prescription drug side effects than ebola.

Every year, nearly 5 million American citizens are sent to the emergency room or to the doctor’s due to precription side effects.

Those innocent patients suffer from pain, discomfort, life-changing drug side effects, expensive medical bills and sometimes the drug side effect cost them their life. Sometimes those patients were fairly warned of the risk. Other times pharmaceutical companies have purposely distorted test results to hide the risks or conducted drug testing that did not adequately uncover the risk of pharmaceutical side effects.

Big Pharma can be held accountable and injured patients can have their medical bills paid for and more.

If you have been the victim of a drug’s side effect, click here to see a list of drug side effects that offer medical compensation.

The post Everything Ebola appeared first on Citizens Report.